Armando Durant Archibold

Dr. Armando Durant Archibold


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
Candelario RodriguezCandelario Rodriguez
Candelario Rodriguez
LRLouise Rollins-Smith
Louise Rollins-Smith
RIRoberto Ibáñez
Roberto Ibáñez
AAArmando Durant Archibold
Armando Durant Archibold
MGMarcelino Gutiérrez
Marcelino Gutiérrez

15 May 2014 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
JLJohant Lakey-Beitia
Johant Lakey-Beitia
RBRuben Berrocal
Ruben Berrocal
Rao KosagisharafRao Kosagisharaf
Rao Kosagisharaf
AAArmando Durant Archibold
Armando Durant Archibold

1 May 2018 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
AAArmando Durant Archibold
Armando Durant Archibold
ASAna I. Santana
Ana I. Santana
MGMahabir Gupta
Mahabir Gupta

1 May 2017 in Clinical Interventions in Aging
Verified
Journal Article
Open access
PDF file
JLJohant Lakey-Beitia
Johant Lakey-Beitia
DDDeborah Doens
Deborah Doens
Jagadeesha Kumar.DJagadeesha Kumar.D
Jagadeesha Kumar.D
EMEnrique Murillo
Enrique Murillo
PFPatricia L. Fernandez
Patricia L. Fernandez
AAArmando Durant Archibold
Armando Durant Archibold
Alzheimer’s disease (AD) is the leading cause of dementia, affecting approximately 33.5 million people worldwide. Aging is the main risk factor associated with AD. Drug discovery based on nutraceutical molecules for prevention and treatment of AD is a growing topic. In this sense, carotenoids are phytochemicals present mainly in fruits and vegetables with reported benefits for human health. In this research, the anti-amyloidogenic activity of three carotenoids, cryptocapsin, cryptocapsin-5,6-epoxide, and zeaxanthin, was assessed. Cryptocapsin showed the highest bioactivity, while cryptocapsin-5,6-epoxide and zeaxanthin exhibited similar activity on anti-aggregation assays. Molecular modeling analysis revealed that the evaluated carotenoids might follow two mechanisms for inhibiting Aβ aggregation: by preventing the formation of the fibril and through disruption of the Aβ aggregates. Our studies provided evidence that cryptocapsin, cryptocapsin-5,6-epoxide, and zeaxanthin have anti-amyloidogenic potential and could be used for prevention and treatment of AD.

15 September 2017 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
JLJohant Lakey-Beitia
Johant Lakey-Beitia
YGYisett González
Yisett González
DDDeborah Doens
Deborah Doens
DSDavid E. Stephens
David E. Stephens
RSRicardo Santamaría
Ricardo Santamaría
AAArmando Durant Archibold
Armando Durant Archibold
Alzheimer’s disease (AD) is the most common neurodegenerative disorder affecting the elderly population worldwide. Brain inflammation plays a key role in the progression of AD. Deposition of senile plaques in the brain stimulates an inflammatory resp

1 February 2014 in Journal of Food Composition and Analysis
Verified
Journal Article
Closed access
EMEnrique Murillo
Enrique Murillo
KRK.S. Rao
K.S. Rao
AAArmando Durant Archibold
Armando Durant Archibold